


CLAIMS

1. A ligand-drug conjugate of a general formula TL-(L-D)_n, or a pharmaceutically acceptable salt or solvate thereof,

wherein TL is a targeting ligand, L is a linker unit, D is Eribulin, and n is a positive integer from 1 to 20;

wherein the ligand-drug conjugate has a structure as shown below:



wherein the targeting ligand is an anti-B7-H3 antibody, wherein heavy-chain complementarity-determining regions HCDR1, HCDR2, and HCDR3 of the anti-B7-H3 antibody are represented by SEQ ID NOs: 1 to 3, respectively, and light-chain complementarity-determining regions LCDR1, LCDR2, and LCDR3 of the anti-B7-H3 antibody are represented by SEQ ID NOs: 4 to 6, respectively.

2. The ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein a heavy chain variable region HCVR of the anti-B7-H3 antibody is represented by SEQ ID NO: 7, and a light chain variable region LCVR of the anti-B7-H3 antibody is represented by SEQ ID NO: 8.

3. The ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to claim 1 or claim 2, wherein a heavy chain constant region of the anti-B7-H3 antibody is represented by SEQ ID NO: 9 or 10, and a light chain constant region of the anti-B7-H3 antibody is represented by SEQ ID NO: 11.

4. The ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to claim 3, wherein the heavy-chain constant region of the anti-B7 H3 antibody is represented by SEQ ID NO: 9.

5. The ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 4, wherein n = 1 to 8.

6. The ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to

any one of claims 1 to 5, wherein $n = 3$ to 5.

7. A method for preparing the ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 6, comprising:

after reduction of the targeting ligand, subjecting the targeting ligand to a conjugation reaction with pre-synthesized -L-D to obtain the compound represented by the general formula of $TL-(L-D)_n$.

8. A pharmaceutical composition, comprising the ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 6, and a pharmaceutically acceptable excipient, diluent, or carrier.

9. Use of the ligand-drug conjugate or the pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 6 in the preparation of a medicament for treating a tumor.

10. The use according to claim 9, wherein the tumor is a solid tumor or hematological tumor such as breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, lung cancer, colon cancer, rectal cancer, colorectal cancer, bone cancer, skin cancer, thyroid cancer, pancreatic cancer, melanoma, glioma, neuroblastoma, glioblastoma multiforme, sarcoma, lymphoma, or leukemia.